GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ChemoMetec AS (CHIX:CHEMMc) » Definitions » EBIT

ChemoMetec AS (CHIX:CHEMMC) EBIT : kr219.1 Mil (TTM As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is ChemoMetec AS EBIT?

ChemoMetec AS's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2024 was kr133.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was kr219.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ChemoMetec AS's annualized ROC % for the quarter that ended in Dec. 2024 was 52.45%. ChemoMetec AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 136.17%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. ChemoMetec AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 2.24%.


ChemoMetec AS EBIT Historical Data

The historical data trend for ChemoMetec AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoMetec AS EBIT Chart

ChemoMetec AS Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.11 113.65 204.70 231.45 176.77

ChemoMetec AS Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 136.80 94.65 90.80 85.97 133.18

Competitive Comparison of ChemoMetec AS's EBIT

For the Medical Devices subindustry, ChemoMetec AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChemoMetec AS's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ChemoMetec AS's EV-to-EBIT falls into.



ChemoMetec AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr219.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ChemoMetec AS  (CHIX:CHEMMc) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ChemoMetec AS's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=252.036 * ( 1 - 22.2% )/( (349.053 + 398.591)/ 2 )
=196.084008/373.822
=52.45 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=676.673 - 31.474 - ( 296.146 - max(0, 98.529 - 489.796+296.146))
=349.053

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=730.218 - 66.891 - ( 264.736 - max(0, 122.704 - 490.923+264.736))
=398.591

Note: The Operating Income data used here is two times the semi-annual (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

ChemoMetec AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=266.358/( ( (92.049 + max(91.482, 0)) + (104.868 + max(102.812, 0)) )/ 2 )
=266.358/( ( 183.531 + 207.68 )/ 2 )
=266.358/195.6055
=136.17 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(62.257 + 119.495 + 5.078) - (31.474 + 0 + 63.874)
=91.482

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(85.095 + 132.715 + 4.588) - (66.891 + 0 + 52.695)
=102.812

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

ChemoMetec AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=219.147/9766.869
=2.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ChemoMetec AS EBIT Related Terms

Thank you for viewing the detailed overview of ChemoMetec AS's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ChemoMetec AS Business Description

Traded in Other Exchanges
Address
Gydevang 43, Allerod, DNK, 3450
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.

ChemoMetec AS Headlines

No Headlines